Drug Profile
Coronavirus vaccine - Sanofi pasteur
Alternative Names: COVID-19Latest Information Update: 28 Mar 2024
At a glance
- Originator National Institute of Allergy and Infectious Diseases; sanofi pasteur
- Developer Biomedical Advanced Research and Development Authority; Sanofi Pasteur
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
- Discontinued Severe acute respiratory syndrome
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 24 Feb 2020 Sanofi Pasteur reinitiates the development of coronavirus vaccine in collaboration with Biomedical Advanced Research and Development Authority
- 18 Feb 2020 Sanofi Pasteur collaborates with Biomedical Advance Research and Development Authority (BARDA) from US Department of Health and Human Services for development of coronavirus vaccine
Development Overview
Introduction
Coronavirus vaccine is an inactivated virus vaccine and is being developed by Sanofi for the prevention of COVID-2019 infections. The development of the vaccine will be based on the prior preclinical studies done on a Severe Acute Respiratory Syndrome (SARS) vaccine candidate and will be done in collaboration with Biomedical Advanced Research And Development Authority (BARDA). Sanofi Pasteur will utlilise its recombinant DNA platform, that produces an exact genetic match to proteins that are found on the surface of the coronavirus. The DNA of baculovirus expression platform will be combined with the DNA sequence encoding the coronavirus antigen. The large quantities of coronavirus antigen generated will in turn be formulated to stimulate the immune system and protect against the virus. Preclinical development is underway in the US.
Earlier Sanofi Pasteur was collaborating with the US National Institute of Allergy and Infectious Diseases (NIAID) to research and develop a SARS vaccine. However, NIAID is no more involved in the development of the vaccine and the development in SARS indication is discontinued.
In January 2005, Aventis Pasteur changed its name to sanofi pasteur.
In February 2022, Sanofi Pasteur has been rebranded under Sanofi [1] .
As at March 2024, no recent reports of development had been identified for preclinical development in COVID-2019-infections (Prevention) in USA (Parenteral).
Company Agreements
In February 2020, Sanofi and US Department of Health and Human Services entered into an agreement to advance the development of a coronavirus vaccine based on Sanofi's previous development work for serious acute respiratory syndrome (SARS) vaccine. Sanofi will work in collaboration with Biomedical Advanced Research And Development Authority (BARDA) and utlilise its recombinant DNA platform, which produces an exact genetic match to proteins that are found on the surface of the coronavirus. The Companies plan a phase IIb study expected to start in February 2021 with support from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) under contract W15QKN-16-9-1002. Other details of the deal are yet to be disclosed. [2] [3]
Aventis Pasteur (later sanofi pasteur) had entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to research and develop an inactivated coronavirus vaccine against Severe Acute Respiratory Syndrome (SARS). Under the agreement, which was signed on 26 September 2003, sanofi pasteur would develop the vaccine candidate using a similar approach to that of the licensed inactivated polio vaccine.
Key Development Milestones
In February 2020, Sanofi announced that the preclinical studies done by Protein Sciences (acquired by Sanofi), prior to 2017, on the SARS vaccine candidate was immunogenic and afforded partial protection in animal challenge models. These results will form a basis for further development of Coronavirus vaccine [2] .
Sanofi pasteur is also participating in the Canadian SARS Research Consortium, a public-private effort to coordinate, promote and support research on SARS, including vaccine development [4] .
Drug Properties & Chemical Synopsis
- Route of administration Parenteral
- Formulation unspecified
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
WHO ATC code
J07B-X (Other viral vaccines)
-
EPhMRA code
J7 (Vaccines)
Table of Contents
Biomarker
| Drug Name | Biomarker Name | Biomarker Function |
|---|---|---|
| Coronavirus vaccine - Sanofi pasteur | (R)-3-Hydroxybutyric acid | Arm Group Label |
| 1-Methylnicotinamide | Outcome Measure | |
| 16S rRNA | Outcome Measure | |
| 2-Pyrocatechuic acid | Arm Group Description | |
| 24,25-Dihydroxyvitamin D | Arm Group Description, Arm Group Label, Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| 25-Hydroxyvitamin D2 | Detailed Description, Outcome Measure | |
| 4-hydroxyphenylpyruvate dioxygenase | Detailed Description, Eligibility Criteria | |
| abhydrolase domain containing 5 | Brief Summary | |
| ACE2 | Arm Group Description, Brief Summary, Brief Title, Detailed Description, Official Title, Outcome Measure | |
| Acetyl-CoA carboxylase 1 (ACC) | Eligibility Criteria | |
| Acetylcysteine | Arm Group Description, Brief Summary, Brief Title, Official Title | |
| ADAM metallopeptidase with thrombospondin type 1 motif, 2 | Brief Title | |
| Adenomatous polyposis coli protein (APC) | Detailed Description | |
| Adenosine | Arm Group Description, Arm Group Label, Brief Summary, Brief Title, Official Title | |
| Adiponectin (ADIPOQ) | Official Title | |
| Aldosterone | Outcome Measure | |
| Alkaline phosphatase (ALPL) | Outcome Measure | |
| Allergic rhinitis | Eligibility Criteria | |
| alpha-1 antitrypsin (SERPINA1) | Outcome Measure | |
| Alpha-D-Glucose | Eligibility Criteria, Outcome Measure | |
| Alpha-Tocopherol | Arm Group Description | |
| ALT | Detailed Description, Eligibility Criteria, Outcome Measure | |
| Angiopoietin 1 | Outcome Measure | |
| Angiotensin II | Brief Title, Detailed Description, Outcome Measure | |
| Angiotensinogen (AGT | Arm Group Description, Arm Group Label, Brief Title, Official Title, Outcome Measure | |
| Annexin A5 | Detailed Description | |
| Anti-neutrophil cytoplasmic antibodies | Eligibility Criteria | |
| argonaute 2, RISC catalytic component | Detailed Description, Eligibility Criteria | |
| Ascorbic acid | Arm Group Description, Arm Group Label, Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| AT-III | Arm Group Description, Arm Group Label, Brief Title, Detailed Description, Official Title, Outcome Measure | |
| ATP-binding cassette, sub-family B (MDR/TAP), member 7 | Outcome Measure | |
| AVP | Brief Title, Detailed Description, Official Title, Outcome Measure | |
| B-lymphocyte antigen CD19 | Outcome Measure | |
| BDNF | Brief Summary, Outcome Measure | |
| bestrophin 1 | Arm Group Description | |
| Bilirubin | Outcome Measure | |
| Biopterin | Detailed Description, Outcome Measure | |
| BiP | Brief Summary, Detailed Description | |
| BMS1, ribosome biogenesis factor | Eligibility Criteria | |
| BNP | Detailed Description, Eligibility Criteria, Outcome Measure | |
| bone marrow stromal cell antigen 1 | Brief Title, Detailed Description, Official Title, Outcome Measure | |
| C-peptide | Outcome Measure | |
| C-reactive protein (CRP) | Arm Group Description, Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| C-X-C motif chemokine ligand 17 | Detailed Description | |
| C1 Inhibitor | Arm Group Description, Arm Group Label | |
| C1QL1 | Detailed Description, Outcome Measure | |
| CA125 ovarian cancer antigen (MUC16) | Outcome Measure | |
| CALCA | Detailed Description, Outcome Measure | |
| Calcitriol | Outcome Measure | |
| calmodulin 3 (phosphorylase kinase, delta) | Brief Summary, Eligibility Criteria | |
| Calprotectin | Brief Summary, Detailed Description, Eligibility Criteria | |
| carcinoembryonic antigen related cell adhesion molecule 6 | Brief Title, Official Title | |
| Cardiac Troponin I | Arm Group Description, Arm Group Label, Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure | |
| Cardiac Troponin T | Arm Group Description, Detailed Description, Eligibility Criteria, Outcome Measure | |
| Cardiolipin auto-antibodies | Outcome Measure | |
| Cardiolipins | Outcome Measure | |
| Caspase-3 (CASP3) | Official Title, Outcome Measure | |
| CBLIF | Detailed Description | |
| CD107a | Outcome Measure | |
| CD109 molecule | Outcome Measure | |
| CD25 (IL2RA) | Detailed Description | |
| CD3 gamma chain (CD3G) | Detailed Description, Outcome Measure | |
| CD38 | Outcome Measure | |
| CD53 molecule | Outcome Measure | |
| CD56 | Detailed Description, Outcome Measure | |
| CD59 molecule, complement regulatory protein | Outcome Measure | |
| CD82 molecule | Eligibility Criteria | |
| CDP-diacylglycerol synthase 1 | Brief Summary | |
| centralopathic epilepsy | Eligibility Criteria | |
| cerebellar ataxia 3 (cerebellar parenchyma disorder 1) | Arm Group Description, Outcome Measure | |
| Cervonoyl ethanolamide | Outcome Measure | |
| CGA | Eligibility Criteria | |
| Chemokine IFN-γ-inducible protein 10 (IP-10/CXCL10) | Brief Summary, Brief Title, Detailed Description, Official Title, Outcome Measure | |
| Cholecalciferol | Arm Group Description, Arm Group Label, Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| chorionic gonadotropin beta subunit 5 | Eligibility Criteria | |
| Chromogranin A | Outcome Measure | |
| chromosome 14 open reading frame 166 | Eligibility Criteria, Outcome Measure | |
| Chromosome 17 | Eligibility Criteria | |
| chromosome 20 open reading frame 181 | Arm Group Label, Official Title | |
| CKB | Detailed Description, Outcome Measure | |
| CKM | Detailed Description, Outcome Measure | |
| clathrin heavy chain | Arm Group Label | |
| Cob(I)alamin | Outcome Measure | |
| Cobalamin | Outcome Measure | |
| Coenzyme Q10 | Brief Summary, Brief Title, Official Title | |
| coiled-coil alpha-helical rod protein 1 | Eligibility Criteria | |
| coiled-coil and C2 domain containing 1A | Brief Title | |
| COPD | Arm Group Description, Arm Group Label, Brief Title, Detailed Description, Eligibility Criteria, Official Title | |
| corticotropin releasing hormone | Detailed Description, Outcome Measure | |
| Creatine | Detailed Description, Eligibility Criteria, Outcome Measure | |
| Creatinine | Arm Group Description, Brief Summary, Detailed Description, Outcome Measure | |
| CREB3L1 | Brief Title, Official Title | |
| CXCL1 | Outcome Measure | |
| Cyanocobalamin | Arm Group Description, Outcome Measure | |
| Cyclic AMP | Arm Group Description, Eligibility Criteria | |
| CYP3A4 | Eligibility Criteria | |
| cystatin A (stefin A) | Detailed Description | |
| Cystatin C | Outcome Measure | |
| Cytidine monophosphate | Outcome Measure | |
| cytoglobin | Eligibility Criteria | |
| D-dimer | Arm Group Description, Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| D-threo-Isocitric acid | Official Title | |
| DAN domain BMP antagonist family member 5 | Detailed Description | |
| DEF6, guanine nucleotide exchange factor | Brief Summary | |
| Dehydroepiandrosterone | Outcome Measure | |
| dipeptidyl peptidase 3 | Eligibility Criteria | |
| dipeptidyl-peptidase 4 | Arm Group Description, Arm Group Label, Brief Title, Official Title | |
| DNA (cytosine-5-)-methyltransferase 3 beta | Eligibility Criteria | |
| Docosahexaenoyl Ethanolamide | Outcome Measure | |
| downstream neighbor of SON | Outcome Measure | |
| DSCR3 arrestin fold containing | Arm Group Description | |
| dsDNA Auto-antibodies | Eligibility Criteria | |
| dymeclin | Detailed Description | |
| E1A binding protein p300 | Outcome Measure | |
| Epidermal growth factor receptor (EGFR) | Arm Group Description, Outcome Measure | |
| Estradiol-17beta 3-sulfate | Brief Summary, Eligibility Criteria, Outcome Measure | |
| Estrogen receptor alpha (ER alpha) | Detailed Description, Eligibility Criteria, Outcome Measure | |
| euchromatic histone-lysine N-methyltransferase 1 | Detailed Description | |
| eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa | Eligibility Criteria, Outcome Measure | |
| eukaryotic translation initiation factor 3 subunit A | Outcome Measure | |
| EVA1C | Outcome Measure | |
| F2-isoprostanes | Outcome Measure | |
| Factor VIII | Outcome Measure | |
| Fc fragment of IgG, low affinity IIIb, receptor (CD16b) | Outcome Measure | |
| Fc gamma RIIIa | Outcome Measure | |
| Ferritin | Arm Group Description, Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure | |
| Fetuin-A | Eligibility Criteria | |
| Fibrinogen | Arm Group Description, Detailed Description, Eligibility Criteria, Outcome Measure | |
| Filamin A | Outcome Measure | |
| FK506 binding protein 5 | Brief Summary, Outcome Measure | |
| FLT4 | Detailed Description, Outcome Measure | |
| Fluticasone | Brief Title | |
| Folic acid | Outcome Measure | |
| Fructosamine | Outcome Measure | |
| FSH | Eligibility Criteria, Outcome Measure | |
| FSHMD1A | Outcome Measure | |
| gamma-glutamyltransferase 2 | Outcome Measure | |
| gamma-glutamyltransferase light chain 1 | Outcome Measure | |
| gamma-glutamyltransferase light chain 3 | Outcome Measure | |
| GBA3 | Eligibility Criteria | |
| GCG | Detailed Description, Outcome Measure | |
| GGT | Outcome Measure | |
| GGTLC4P | Outcome Measure | |
| GGTLC5P | Outcome Measure | |
| GLP1R | Detailed Description | |
| Glutathione | Brief Title, Detailed Description, Outcome Measure | |
| Glycerol | Arm Group Description | |
| GNPTAB | Detailed Description, Eligibility Criteria, Outcome Measure | |
| GR | Brief Summary, Outcome Measure | |
| Granulocyte-macrophage colony-stimulating factor (GM-CSF) | Arm Group Description, Detailed Description, Outcome Measure | |
| GRHL3 | Outcome Measure | |
| growth differentiation factor 10 | Brief Summary, Detailed Description | |
| growth hormone 1 | Outcome Measure | |
| Gut Microbiome | Brief Title, Official Title | |
| HBEGF | Eligibility Criteria | |
| heat shock 22kDa protein 8 | Detailed Description | |
| heat shock 27kDa protein 3 | Eligibility Criteria | |
| HER2/ERBB2 | Brief Summary, Brief Title, Eligibility Criteria, Official Title | |
| HFE | Eligibility Criteria | |
| histocompatibility minor 13 | Detailed Description | |
| HLA-A | Eligibility Criteria | |
| HLA-DR | Outcome Measure | |
| homeobox D13 | Outcome Measure | |
| hormonally up-regulated Neu-associated kinase | Outcome Measure | |
| Human Microbiome | Brief Title, Detailed Description, Official Title | |
| Hydrocortisone | Arm Group Description, Arm Group Label, Brief Title, Detailed Description, Official Title, Outcome Measure | |
| hypertrichosis 2 (generalized, congenital) | Eligibility Criteria | |
| ICAM-1 (Intercellular Adhesion Molecule 1) | Outcome Measure | |
| IFN-alpha 2 | Arm Group Description, Outcome Measure | |
| IGF1 | Outcome Measure | |
| IGFBP1 | Detailed Description | |
| Inducible T cell co-stimulator (ICOS) | Official Title | |
| Inosine triphosphate | Eligibility Criteria | |
| Insulin | Arm Group Description, Arm Group Label, Brief Summary, Brief Title, Detailed Description, Official Title, Outcome Measure | |
| Interferon alpha (IFN-alpha) | Brief Summary, Outcome Measure | |
| Interferon Gamma (IFNg) | Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| interferon, beta 1, fibroblast | Outcome Measure | |
| Interferon-stimulated gene of 20 kDa protein (ISG20) | Detailed Description | |
| Interleukin 1 alpha (IL-1α) | Detailed Description, Outcome Measure | |
| Interleukin 1 Beta (IL-1β) | Detailed Description, Outcome Measure | |
| Interleukin-1 receptor antagonist (IL-1RA) | Arm Group Description, Brief Title, Official Title | |
| Interleukin-10 (IL-10) | Detailed Description, Outcome Measure | |
| Interleukin-12A (IL-12p35) | Detailed Description, Outcome Measure | |
| Interleukin-12B (IL-12p40) | Detailed Description, Outcome Measure | |
| Interleukin-13 (IL-13) | Detailed Description, Outcome Measure | |
| Interleukin-17 (IL-17) | Detailed Description, Outcome Measure | |
| Interleukin-18 (IL-18) | Outcome Measure | |
| Interleukin-2 (IL-2) | Detailed Description, Outcome Measure | |
| Interleukin-4 (IL-4) | Brief Summary, Detailed Description, Outcome Measure | |
| Interleukin-5 (IL-5) | Detailed Description, Outcome Measure | |
| Interleukin-6 (IL-6) | Arm Group Description, Brief Summary, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| Interleukin-7 (IL-7) | Outcome Measure | |
| Interleukin-8 (IL-8) | Detailed Description, Outcome Measure | |
| IQ motif containing GTPase activating protein 1 | Arm Group Description | |
| kallikrein related peptidase 4 | Brief Title, Official Title | |
| keratin 10, type I | Eligibility Criteria, Outcome Measure | |
| keratin 7 | Outcome Measure | |
| KIM-1 | Outcome Measure | |
| KRT88P | Eligibility Criteria | |
| L-Aspartic acid | Eligibility Criteria, Outcome Measure | |
| L-Glutamine | Arm Group Description, Arm Group Label, Brief Title, Official Title | |
| L-Lactic acid | Outcome Measure | |
| Lactate dehydrogenase (LDH) | Brief Summary, Detailed Description, Outcome Measure | |
| Lactoferrin | Arm Group Label, Detailed Description | |
| latent transforming growth factor beta binding protein 3 | Arm Group Description, Outcome Measure | |
| Leptin | Official Title | |
| LIF | Outcome Measure | |
| lipase, family member N | Eligibility Criteria | |
| LOC102724197 | Outcome Measure | |
| LOC107988038 | Eligibility Criteria | |
| MAFIP | Detailed Description | |
| major intrinsic protein of lens fiber | Detailed Description | |
| Maleic acid | Arm Group Description, Brief Title, Official Title | |
| Malondialdehyde | Detailed Description | |
| mannose-binding lectin (protein C) 2, soluble | Eligibility Criteria | |
| matrilin 1, cartilage matrix protein | Outcome Measure | |
| matrix metallopeptidase 7 | Brief Summary, Official Title, Outcome Measure | |
| MAX network transcriptional repressor | Brief Summary, Outcome Measure | |
| MBL3P | Eligibility Criteria | |
| Melatonin | Arm Group Description, Arm Group Label, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| metaxin 1 | Outcome Measure | |
| metaxin 3 | Arm Group Description | |
| methyl-CpG binding domain protein 1 | Detailed Description | |
| MHC class I antigen HLA-A heavy chain (HLA-A) | Eligibility Criteria | |
| microRNA 155 | Outcome Measure | |
| microRNA 21 | Outcome Measure | |
| MIF | Outcome Measure | |
| miR-146a | Outcome Measure | |
| mitochondrial intermediate peptidase | Detailed Description | |
| mitogen-activated protein kinase associated protein 1 | Outcome Measure | |
| MMP-2 | Outcome Measure | |
| MMP9 | Brief Summary, Detailed Description, Official Title, Outcome Measure | |
| Monocyte chemoattractant protein-1 (MCP-1/CCL2) | Detailed Description, Outcome Measure | |
| MPO | Arm Group Description, Outcome Measure | |
| MTRNR2L3 | Eligibility Criteria | |
| musculin | Arm Group Description, Brief Summary, Brief Title, Eligibility Criteria, Official Title | |
| mutated in colorectal cancers | Brief Summary | |
| myelin basic protein | Eligibility Criteria | |
| myoglobin | Detailed Description, Eligibility Criteria, Outcome Measure | |
| Neopterin | Detailed Description, Outcome Measure | |
| neural proliferation, differentiation and control 1 | Detailed Description | |
| Neurofilament Light Chain (NF-L) | Outcome Measure | |
| neuropeptide S | Eligibility Criteria | |
| NGAL | Outcome Measure | |
| Niacinamide | Arm Group Label, Brief Title, Official Title | |
| Nicotinic acid adenine dinucleotide | Outcome Measure | |
| Nitric Oxide (NO) | Arm Group Description, Arm Group Label, Brief Title, Official Title | |
| NLR family, pyrin domain containing 3 | Arm Group Description | |
| Norepinephrine | Eligibility Criteria | |
| OPRM1 | Outcome Measure | |
| Oxalacetic acid | Arm Group Description, Arm Group Label | |
| Oxytocin | Outcome Measure | |
| oxytocin receptor | Brief Summary, Outcome Measure | |
| PAI-1 | Detailed Description, Outcome Measure | |
| PAMG-1 | Eligibility Criteria | |
| PDGFRA | Arm Group Description | |
| PDGFRB | Arm Group Description | |
| PDZ and LIM domain 7 | Eligibility Criteria | |
| peptidylprolyl isomerase G | Eligibility Criteria | |
| PHGDH | Arm Group Label | |
| phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha | Eligibility Criteria, Outcome Measure | |
| Phosphonoacetate | Outcome Measure | |
| PITRM1 | Arm Group Label, Brief Summary, Brief Title, Official Title | |
| PKD2L1 | Detailed Description, Outcome Measure | |
| polymerase (DNA) alpha 1, catalytic subunit | Outcome Measure | |
| post-GPI attachment to proteins 1 | Brief Title, Detailed Description, Official Title, Outcome Measure | |
| Potocki-Shaffer syndrome | Outcome Measure | |
| pregnancy specific beta-1-glycoprotein 1 | Detailed Description | |
| Prieto X-linked mental retardation syndrome | Outcome Measure | |
| pro-melanin concentrating hormone | Outcome Measure | |
| Pro-opiomelanocortin (POMC | Detailed Description, Eligibility Criteria, Outcome Measure | |
| Prolactin | Outcome Measure | |
| proteasome subunit beta 4 | Eligibility Criteria | |
| protein phosphatase 4 catalytic subunit | Detailed Description | |
| protein phosphatase 6 regulatory subunit 2 | Detailed Description | |
| protein tyrosine phosphatase, non-receptor type 6 | Arm Group Description, Eligibility Criteria | |
| proteoglycan 2, pro eosinophil major basic protein | Eligibility Criteria | |
| Prothrombin (PT) | Detailed Description, Outcome Measure | |
| PTH | Outcome Measure | |
| PYD and CARD domain containing | Eligibility Criteria | |
| RAGE | Outcome Measure | |
| RAS | Brief Summary, Detailed Description | |
| regulatory associated protein of MTOR, complex 1 | Outcome Measure | |
| Renin | Brief Title, Detailed Description, Official Title, Outcome Measure | |
| ribosomal oxygenase 1 | Brief Summary, Outcome Measure | |
| ribosomal oxygenase 2 | Brief Summary, Outcome Measure | |
| ribosomal protein S13 | Detailed Description | |
| ribosome binding protein 1 | Outcome Measure | |
| sarcosine dehydrogenase | Brief Title | |
| secretion associated Ras related GTPase 1A | Arm Group Description | |
| selenocysteine lyase | Outcome Measure | |
| serpin family A member 6 | Eligibility Criteria | |
| serpin family B member 2 | Detailed Description | |
| serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 | Detailed Description | |
| SERPINF2 | Detailed Description | |
| seryl-tRNA synthetase | Arm Group Description, Brief Summary, Brief Title, Eligibility Criteria, Official Title, Outcome Measure | |
| seryl-tRNA synthetase 2, mitochondrial | Eligibility Criteria | |
| SET domain containing 2 | Eligibility Criteria | |
| sex hormone-binding globulin | Eligibility Criteria, Outcome Measure | |
| SH3 and cysteine rich domain 3 | Outcome Measure | |
| small nucleolar RNA, C/D box 118 | Outcome Measure | |
| SOD1 | Detailed Description | |
| solute carrier family 6 (neurotransmitter transporter), member 4 | Brief Summary, Outcome Measure | |
| Sp1 transcription factor | Detailed Description | |
| Sp2 transcription factor | Detailed Description | |
| Sp6 transcription factor | Eligibility Criteria | |
| Spermidine | Outcome Measure | |
| spermine synthase | Detailed Description, Eligibility Criteria | |
| succinate dehydrogenase complex, subunit D, integral membrane protein | Arm Group Label | |
| Surfactant protein D | Outcome Measure | |
| Syndecan-1 (SDC1 | Detailed Description, Outcome Measure | |
| T cell receptor beta variable 20/OR9-2 (non-functional) | Arm Group Description | |
| T-cell activation antigen CD27 (TNFRSF7) | Outcome Measure | |
| T-Cell differentiation antigen CD8 | Brief Summary, Detailed Description, Outcome Measure | |
| T-cell receptor CD3-epsilon (CD3e) | Detailed Description, Outcome Measure | |
| T-cell receptor T3 delta chain (CD3d) | Detailed Description, Outcome Measure | |
| T-cell surface antigen CD4 | Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure | |
| TAL1 | Outcome Measure | |
| TBL1XR1 | Brief Summary | |
| TCAP | Brief Title | |
| TEN1 CST complex subunit | Brief Summary | |
| Testosterone | Brief Summary, Detailed Description, Eligibility Criteria, Outcome Measure | |
| TF | Detailed Description, Outcome Measure | |
| Thrombomodulin | Outcome Measure | |
| Thymidylate synthetase | Eligibility Criteria | |
| Thyroglobulin | Outcome Measure | |
| Thyroid stimulating hormone beta (TSH) | Detailed Description, Eligibility Criteria, Outcome Measure | |
| TIMP-1 | Detailed Description | |
| tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) | Outcome Measure | |
| Tissue Plasminogen Activator (tPA) | Arm Group Description, Arm Group Label, Official Title | |
| TPO | Detailed Description, Outcome Measure | |
| TPO Auto-antibodies | Detailed Description, Outcome Measure | |
| trafficking protein particle complex 9 | Brief Summary | |
| Transforming growth factor-beta (TGF-beta) | Brief Summary, Official Title, Outcome Measure | |
| translocator protein | Brief Summary | |
| transmembrane protease, serine 2 | Brief Title, Official Title | |
| transportin 1 | Detailed Description, Outcome Measure | |
| Transthyretin | Outcome Measure | |
| triggering receptor expressed on myeloid cells 1 | Brief Title, Official Title, Outcome Measure | |
| Tumor necrosis factor alpha (TNF-alpha) | Detailed Description, Official Title, Outcome Measure | |
| ubiquitin specific peptidase 1 | Arm Group Description | |
| Vanillin | Brief Title, Official Title | |
| Vascular endothelial growth factor A (VEGF) | Detailed Description, Outcome Measure | |
| Vasopressin | Eligibility Criteria | |
| visual system homeobox 1 | Detailed Description, Eligibility Criteria | |
| Vitamin A | Arm Group Description, Outcome Measure | |
| Vitamin D3 | Arm Group Description, Arm Group Label, Brief Summary, Brief Title, Detailed Description, Eligibility Criteria, Official Title, Outcome Measure | |
| vitronectin | Arm Group Description, Arm Group Label, Detailed Description, Outcome Measure | |
| Von Willebrand factor | Outcome Measure | |
| WNT1 inducible signaling pathway protein 3 | Detailed Description, Eligibility Criteria | |
| Y Chromosome | Eligibility Criteria | |
| ZGLP1 | Detailed Description | |
| zinc finger protein 415 | Arm Group Description, Brief Title |
For more detail, check out BiomarkerBase: the leading source of information about biomarkers used in drug development and diagnostic tests, tracking a comprehensive list of biomarker uses worldwide by over 800 companies
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| COVID 2019 infections | - | Prevention | No development reported (Preclinical) | USA | Parenteral / unspecified | Biomedical Advanced Research and Development Authority, Sanofi Pasteur | 28 Mar 2024 |
| Severe acute respiratory syndrome | - | - | Discontinued (Preclinical) | France | unspecified / unspecified | Sanofi Pasteur | 30 Dec 2005 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| sanofi pasteur | Originator | France |
| National Institute of Allergy and Infectious Diseases | Originator | USA |
| Sanofi | Owner | France |
| Biomedical Advanced Research and Development Authority | Collaborator | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Mar 2024 | Phase Change - No development reported | No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in USA (Parenteral) Updated 28 Mar 2024 |
| 03 Feb 2022 | Company Involvement | Sanofi Pasteur has been rebranded under Sanofi Updated 04 Apr 2022 |
| 14 Jan 2022 | Biomarker Update | Biomarkers information updated Updated 16 Jan 2022 |
| 24 Feb 2020 | Active Status Review | Sanofi Pasteur reinitiates the development of coronavirus vaccine in collaboration with Biomedical Advanced Research and Development Authority [2] Updated 02 Mar 2020 |
| 18 Feb 2020 | Company Involvement | Sanofi Pasteur collaborates with Biomedical Advance Research and Development Authority (BARDA) from US Department of Health and Human Services for development of coronavirus vaccine [2] Updated 02 Mar 2020 |
| 18 Feb 2020 | Phase Change - Preclinical | Preclinical trials in COVID-2019-infections (Prevention) in USA (Parenteral) [2] Updated 02 Mar 2020 |
| 30 Dec 2005 | Phase Change - Discontinued(Preclinical) | Discontinued - Preclinical for Severe acute respiratory syndrome in France (unspecified route) Updated 17 Mar 2009 |
| 19 Jan 2005 | Company Involvement | Aventis Pasteur is now called sanofi pasteur Updated 19 Jan 2005 |
| 27 Aug 2004 | Company Involvement | Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis Updated 27 Aug 2004 |
| 20 Oct 2003 | Phase Change - Preclinical | Preclinical trials in Severe acute respiratory syndrome in France (unspecified route) Updated 20 Oct 2003 |
References
-
Press Release: Sanofi unveils new corporate brand and logo - unites the company under one purpose and a single identity.
Media Release -
Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine.
Media Release -
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly.
Media Release -
Aventis and NIH Enter Into SARS Vaccine R&D Pact.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG